Antineoplastic Combined Chemotherapy Protocols/*therapeutic use Chemotherapy Adjuvant Cisplatin/administration & dosage *Cystectomy/methods Evidence-Based Medicine Humans *Lymph Node Excision Neoadjuvant Therapy/*methods Neoplasm Invasiveness Organ Sparing Treatments/methods Randomized Controlled Trials as Topic Survival Analysis Treatment Outcome Urinary Bladder Neoplasms/mortality/*pathology/*therapy adjuvant chemotherapy bladder cancer bladder-sparing therapy lymph node dissection neoadjuvant chemotherapy radical cystectomy

Controlled Clinical Trials as Topic Cystectomy/*methods Female Humans Male *Quality of Life Reproducibility of Results Surveys and Questionnaires Treatment Outcome Urinary Bladder Neoplasms/pathology/psychology/*surgery Urinary Diversion/methods/*psychology *Urinary Reservoirs Continent Health related quality of life Ileal conduit Meta-analysis Orthotopic neobladder Radical cystectomy Urinary diversion

Humans *Hyperthermia Induced Treatment Outcome Urinary Bladder Neoplasms/*therapy Bladder cancer chemohyperthermia radiohyperthermia regional hyperthermia therapy urothelial carcinoma

Diet Exercise Female Humans Male Meta-Analysis as Topic Occupational Exposure/adverse effects Occupations Risk Factors Smoking/adverse effects Urinary Bladder Neoplasms/*etiology/prevention & control Bladder cancer Lifestyle Obesity Occupation Prevention Smoking

Adult Aged Aged 80 and over Antibodies Monoclonal/therapeutic use Antibodies Monoclonal Humanized/therapeutic use B7-H1 Antigen/*antagonists & inhibitors/genetics CTLA-4 Antigen/*antagonists & inhibitors/genetics Clinical Trials as Topic Female Genes cdc/drug effects Humans Ipilimumab Male Middle Aged Neoplasm Metastasis/*drug therapy/genetics/pathology Nivolumab Urinary Bladder Neoplasms/*drug therapy/genetics/pathology Bladder cancer immunotherapy Checkpoint inhibitor Pembrolizumab

*Aminolevulinic Acid Cystectomy/methods Disease-Free Survival Humans Neoplasm Recurrence Local *Photosensitizing Agents Randomized Controlled Trials as Topic Urinary Bladder Neoplasms/diagnostic imaging/*surgery 5-aminolevulinic acid non-muscle invasive bladder cancer photodynamic diagnosis recurrence-free survival transurethral resection

Biomarkers Tumor/*blood/*genetics Humans MicroRNAs/*blood/*genetics Neoplasm Invasiveness Reverse Transcriptase Polymerase Chain Reaction Urinary Bladder Neoplasms/*blood/*genetics/pathology

Critical Pathways Cystectomy/*methods/rehabilitation Humans Length of Stay Postoperative Care/*methods Postoperative Complications/*epidemiology *Standard of Care Urinary Bladder Neoplasms/*surgery Urinary Diversion/*methods/rehabilitation Clinical pathways Collaborative care Cystectomy Enhanced recovery Fast track including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg employment/affiliation grants or funding consultancies honoraria stock ownership or options expert testimony royalties or patents filed received or pending) are the following: None.

biomarker diagnosis meta-analysis microRNA muscle-invasive bladder cancer